Hollis Johnson
Popular spit-in-a-tube genetics testing companies like Ancestry and 23andMe can — and frequently do — sell your data to drug makers. But on Wednesday, one of those partnerships became much more explicit: pharmaceutical giant GlaxoSmithKline announced it was acquiring a $300 million stake in 23andMe.
As part of a 4-year deal between the two companies, GlaxoSmithKline will comb 23andMe's genetic data to look for potential new drugs to develop, also referred to as drug targets. It will also use the genetic data to inform how patients are selected for clinical trials.See the rest of the story at Business Insider
NOW WATCH: 5 science facts that 'Jurassic World: Fallen Kingdom' totally ignored
See Also:
The head of a top anti-tobacco group says an e-cig that's gone viral among teens is ‘the genie you can’t put back in the bottle’A startup backed by Peter Thiel has churned out 20,000 doses of magic mushrooms, and is making morePharmaceutical companies are backing away from a growing threat that could kill 10 million people a year by 2050DON'T MISS: Why pharma giant GSK just made a $300 million bet on 23andMe's approach to finding new medicines
Read more: feedproxy.google.com
No comments:
Post a Comment